281 related articles for article (PubMed ID: 28074487)
21. Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.
Lucas Ramos J; Suárez Ferrer C; Poza Cordón J; Sánchez Azofra M; Rueda García JL; Martin Arranz E; Yebra Carmona J; Andaluz García I; Martín Arranz MD
Gastroenterol Hepatol; 2021 May; 44(5):337-345. PubMed ID: 33272733
[TBL] [Abstract][Full Text] [Related]
22. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP
Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972
[TBL] [Abstract][Full Text] [Related]
24. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis.
Chitul A; Voiosu AM; Marinescu M; Caraiola S; Nicolau A; Badea GC; Pârvu MI; Ionescu RA; Mateescu BR; Voiosu MR; Băicuş CR; Rimbaş M
Rom J Intern Med; 2017 Mar; 55(1):44-52. PubMed ID: 28103201
[TBL] [Abstract][Full Text] [Related]
25. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
26. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
[TBL] [Abstract][Full Text] [Related]
27. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.
Beigel F; Schnitzler F; Paul Laubender R; Pfennig S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Inflamm Bowel Dis; 2011 Jan; 17(1):91-8. PubMed ID: 20564536
[TBL] [Abstract][Full Text] [Related]
28. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
[TBL] [Abstract][Full Text] [Related]
29. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
30. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
[TBL] [Abstract][Full Text] [Related]
31. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
[TBL] [Abstract][Full Text] [Related]
32. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
33. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
[TBL] [Abstract][Full Text] [Related]
34. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
[TBL] [Abstract][Full Text] [Related]
35. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
[TBL] [Abstract][Full Text] [Related]
36. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
37. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
[TBL] [Abstract][Full Text] [Related]
38. Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease.
Calloway A; Dalal R; Beaulieu DB; Duley C; Annis K; Gaines L; Slaughter C; Schwartz DA; Horst S
Dig Dis Sci; 2017 Dec; 62(12):3563-3567. PubMed ID: 29052816
[TBL] [Abstract][Full Text] [Related]
39. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
40. Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
van der Have M; Oldenburg B; Kaptein AA; Jansen JM; Scheffer RC; van Tuyl BA; van der Meulen-de Jong AE; Pierik M; Siersema PD; van Oijen MG; Fidder HH
J Crohns Colitis; 2016 May; 10(5):549-55. PubMed ID: 26738757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
